

Special Issue

Molecular Epidemiology and Pathophysiology of Autoimmune Encephalitis

Message from the Guest Editors

Autoimmune encephalitis encompasses a broad range of diseases with different pathophysiology. Largely due to their rarity and heterogenous nature, these encephalitises are challenging to treat, and frequently recur. Over the last decade, significant progress has been made, providing a better understanding of their physiopathology.

The aim of this Special Issue is to provide a broad overview of the molecular epidemiology and pathophysiological mechanisms that drive autoimmune encephalitis. Overall, the goal is to highlight progress made in preclinical and translational research to improve our understanding of autoimmune encephalitis. We invite both original research and review articles highlighting recent advances in the field of autoimmune encephalitis.

- autoimmune encephalitis
- neuronal surface antibody
- antineuronal nuclear antibody
- paraneoplastic syndrome
- limbic encephalitis
- encephalomyelitis

Guest Editors

Dr. Agusti Alentorn
Dr. Dimitri Psimaras
Dr. Bastien Joubert

Deadline for manuscript submissions

closed (15 July 2022)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 7.8
Indexed in PubMed



mdpi.com/si/96598

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 7.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).